<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:0ba989d1-8732-472d-8ac8-e5fc57cd0783"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="9a0d106d-dd71-47dd-936e-0a6a192ad483"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-04T12:11:12Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:c388aedc-e954-4d0d-9269-54e6d4df5b94"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<contained>
                                <Binary>
                                	<id value="image0"/>
                                	<!-- example format -->
                                	<contentType value="AbilifyMaintena-h-2755-e_files/image001.png"/>
									<!-- data is base 64 encoded, actual bytes of the image png file -->
                                	<data value="AbilifyMaintena-h-2755-e_files/image001.png"/>
								</Binary>
							</contained>
							<!-- this exension is necessary per image -->
                        	<extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                        		<valueReference>
                        			<reference value="#image0"/>
                        		</valueReference>
                        	</extension>
							
							<status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="TitleA"><span lang="EN-GB">SUMMARY OF PRODUCT CHARACTERISTICS</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">1.       NAME OF THE MEDICINAL PRODUCT</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each vial contains 300 mg aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each vial contains 400 mg aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each pre‑filled syringe contains 300 mg aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each pre‑filled syringe contains 400 mg aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After reconstitution each ml of suspension contains 200 mg aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">For the full list of excipients, see section 6.1.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">3.       PHARMACEUTICAL FORM</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Powder and solvent for prolonged-release suspension for injection</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Powder: white to off-white</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Solvent: clear solution</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.       CLINICAL PARTICULARS</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.1     Therapeutic indications</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.2     Posology and method of administration</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Posology</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">For patients who have never taken aripiprazole, tolerability with oral aripiprazole must occur prior to initiating treatment with Abilify Maintena.</span></em></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Titration of the dose </span></em><em><span lang="EN-GB" style="color:black;font-style: normal">for Abilify Maintena is not required. </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The </span></em><em><span lang="EN-GB" style="color:black;font-style:normal">starting dose can be administered by following one of two regimens: </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        One injection start: On the day of initiation, administer one injection of 400 mg Abilify Maintena and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy. </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        Two injection start: On the day of initiation, administer two separate injections of 400 mg Abilify Maintena at separate injection sites (see method of administration), along with one 20 mg dose of oral aripiprazole. </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After the </span></em><em><span lang="EN-GB" style="color:black;font-style:normal">injection start, the </span></em><em><span lang="EN-GB" style="color:black;font-style:normal">recommended maintenance dose of Abilify Maintena is 400 mg.</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> Abilify Maintena</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em><em><span lang="EN-GB" style="color:black;font-style:normal">If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Missed doses</span></u></em></p><p class="MsoNormal" style="margin-left:.5in"><em><span lang="EN-GB" style="color:black;background:yellow;font-style:normal"> </span></em></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none" width="614"> <tr> <td colspan="2" style="width:460.7pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="614"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Missed doses</span></b></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Timing of Missed Dose</span></b></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Action</span></b></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">If 2<sup>nd</sup> or 3<sup>rd</sup> dose is missed and time   since last injection is:</span></b></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal"> </span></b></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">&gt; 4 weeks   and &lt; 5 weeks </span></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The   injection should be administered as soon as possible and then the monthly   injection schedule should be resumed.</span></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">&gt; 5 weeks   </span></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Concomitant   oral aripiprazole should be restarted for 14 days with next administered   injection</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">   or two separate injections given at one time, along with a single dose of 20 mg   oral aripiprazole. Monthly injection schedule should then resume</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">.</span></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">If 4<sup>th</sup> or subsequent doses are missed (i.e., after   attainment of steady state) and time since last injection is:</span></b></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal"> </span></b></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">&gt; 4 weeks   and &lt; 6 weeks</span></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The   injection should be administered as soon as possible and then the monthly   injection schedule should be resumed.</span></em></p> </td> </tr> <tr> <td style="width:184.3pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="246"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">&gt; 6 weeks</span></em></p> </td> <td style="width:276.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="369"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Concomitant   oral aripiprazole should be restarted for 14 days with next administered   injection </span></em><em><span lang="EN-GB" style="color:black;font-style:   normal">or two separate injections given at one time, along with a single   dose of 20 mg oral aripiprazole. Monthly</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> injection schedule</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> should then resume</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">.</span></em></p> </td> </tr> </table><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Special populations</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Elderly</span></em></p><p class="MsoNormal"><span lang="EN-GB">The safety and efficacy of <em><span style="color:black;font-style:normal">Abilify Maintena</span></em> in the treatment of schizophrenia in patients 65 years of age or older has not been established (see section 4.4).</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Renal impairment</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">No dosage adjustment is required for patients with renal impairment (see section 5.2).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Hepatic impairment</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">No dosage adjustment is required for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. Oral formulation should be preferred (see section 5.2).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><a name="_Hlk23773509"><em><span lang="EN-GB" style="color:black">Known CYP2D6 poor metabolisers</span></em></a></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In patients who are known to be CYP2D6 poor metabolisers</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">: </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        One injection start: The starting dose should be 300 mg Abilify Maintena and continue treatment with prescribed dose of oral aripiprazole per day for 14 consecutive days. </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        Two injection start: The starting dose should be 2 separate injections of 300 mg Abilify Maintena (see method of administration) along with one single dose of the previous prescribed dose of oral aripiprazole. </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In patients who are known to be CYP2D6 poor metabolisers and concomitantly use a strong CYP3A4 inhibitor:</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        The one injection start: The starting dose should be reduced to 200 mg (see section 4.5) and continue treatment with the prescribed dose of oral aripiprazole per day for 14 consecutive days.</span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal">•        Two injection start is not to be used in patients who are known to be CYP2D6 poor metabolisers and concomitantly use a strong CYP3A4 inhibitor.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After the injection start, see table below for the recommended maintenance dose of Abilify Maintena. Abilify Maintena should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).</span></em></p><p class="MsoNormal" style="margin-left:.25in"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Maintenance dose</span></em><em><span lang="EN-GB" style="color:black"> adjustments due to interactions </span></em><i><span lang="EN-GB" style="color:black">with CYP2D6 and/or CYP3A4 inhibitors and/or CYP3A4 inducers</span></i></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Maintenance dosage</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> adjustments should be made in patients taking concomitant strong CYP3A4 inhibitors or strong CYP2D6 inhibitors for more than 14 days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be increased to the previous dose (see section 4.5). In case of adverse reactions despite dose adjustments of Abilify Maintena, the necessity of concomitant use of CYP2D6 or CYP3A4 inhibitor should be reassessed.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section 4.5).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Maintenance dose</span></b></em><em><b><span lang="EN-GB" style="color:black;font-style:normal"> adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days</span></b></em></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:460.7pt;margin-left:5.4pt;border-collapse:collapse;border:none" width="614"> <tr style="height:22.45pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:22.45pt" valign="top" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p> </td> <td style="width:177.2pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.45pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Adjusted dose</span></b></em></p> </td> </tr> <tr style="height:11.2pt"> <td colspan="2" style="width:460.7pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt" valign="top" width="614"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Patients taking 400 mg of Abilify Maintena</span></b></em></p> </td> </tr> <tr style="height:11.2pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.2pt" valign="top" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Strong   CYP2D6 or strong CYP3A4 inhibitors</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.2pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">300 mg</span></em></p> </td> </tr> <tr style="height:13.0pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.0pt" valign="top" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Strong   CYP2D6 and strong CYP3A4 inhibitors</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:13.0pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">200 mg*</span></em></p> </td> </tr> <tr style="height:11.65pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">CYP3A4   inducers</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:11.65pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">Avoid use</span></em></p> </td> </tr> <tr style="height:8.95pt"> <td colspan="2" style="width:460.7pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt" valign="top" width="614"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Patients taking 300 mg of Abilify Maintena</span></b></em></p> </td> </tr> <tr style="height:8.5pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Strong   CYP2D6 or strong CYP3A4 inhibitors</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.5pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">200 mg*</span></em></p> </td> </tr> <tr style="height:8.95pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.95pt" valign="top" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Strong   CYP2D6 and strong CYP3A4 inhibitors</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:8.95pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">160 mg*</span></em></p> </td> </tr> <tr style="height:14.35pt"> <td style="width:283.5pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt" width="378"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">CYP3A4   inducers</span></em></p> </td> <td style="width:177.2pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:14.35pt" valign="top" width="236"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">Avoid use</span></em></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><em><span lang="EN-GB" style="font-size:8.0pt;font-style:normal">*    </span></em><span lang="EN-GB" style="font-size:8.0pt">200 mg and 160 mg can be achieved via adjustment of the injection volume only by using Abilify Maintena powder and solvent for </span><span lang="EN-GB" style="font-size:8.0pt"> </span><span lang="EN-GB" style="font-size:8.0pt">prolonged-release suspension for injection.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Paediatric population</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The safety and efficacy of Abilify Maintena in children and adolescents aged 0‑17 years have not been established. No data are available.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Method of administration</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena is only intended for intramuscular use and should not be administered intravenously or subcutaneously. It should only be administered by a healthcare professional.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The suspension should be injected slowly as a single injection (doses must not be divided) into the gluteal or deltoid muscle. Care should be taken to avoid inadvertent injection into a blood vessel.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">If initiating with the two injection start, inject into two different sites in two different muscles. DO NOT inject both injections concomitantly into the same deltoid or gluteal muscle.</span><span lang="EN-GB" style="color:#0070C0"> </span><span lang="EN-GB">For known CYP2D6 poor metabolisers administer in either two separate deltoid muscles or one deltoid and one gluteal muscle. DO NOT inject into two gluteal muscles.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Full instructions for use and handling of Abilify Maintena are provided in the package leaflet (information intended for healthcare professionals).</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">For instructions on reconstitution of the medicinal product before administration, see section 6.6.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.3     Contraindications</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.4     Special warnings and precautions for use</span></b></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="font-style:normal">During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</span></em></p><p class="MsoNormal"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><u><span lang="EN-GB">Use in patients who are in an acutely agitated or severely psychotic state</span></u></p><p class="MsoNormal"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><span lang="EN-GB">Abilify Maintena should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Suicidality</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The occurrence of suicidal behaviour is inherent in psychotic illnesses, and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). Close supervision of high risk patients should accompany antipsychotic treatment.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Cardiovascular disorders</span></u></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">QT prolongation</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tardive dyskinesia</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Neuroleptic Malignant Syndrome (NMS)</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Seizure</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</span></em></p><p class="MsoNormal"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal"><u><span lang="EN-GB">Elderly patients with dementia-related psychosis</span></u></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Increased mortality</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In three placebo-controlled trials of oral aripiprazole in elderly patients with psychosis associated with Alzheimer's disease (n = 938; mean age: 82.4 years; range: 56‑99 years), patients treated with aripiprazole were at an increased risk of death compared to placebo. The rate of death in oral aripiprazole-treated patients was 3.5 % compared to 1.7 % in placebo. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</span></p><p class="MsoNormal"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><i><span lang="EN-GB">Cerebrovascular adverse reactions</span></i></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">In the same trials with oral aripiprazole, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78‑88 years). Overall, 1.3 % of oral aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose- response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole</span></em><span lang="EN-GB" style="color:black"> is not indicated for the treatment of patients with dementia-related psychosis.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Hyperglycaemia and diabetes mellitus</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. Patients treated with aripiprazole should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Hypersensitivity</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="text-autospace:none"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Weight gain</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;background:yellow; font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Weight gain is commonly seen in schizophrenic patients due to use of antipsychotics known to cause weight gain, co-morbidities, poorly managed life-style and might lead to severe complications. <em><span style="font-style:normal">Weight gain has been reported post-marketing among patients prescribed oral aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 4.8).</span></em></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Dysphagia</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Oesophageal dysmotility and aspiration have been associated with the use of aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></u></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medicinal productation was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. </span></em><span lang="EN-GB">A dose reduction or stopping of the medicinal product should be considered if a patient develops such urges <em><span style="color:black; font-style:normal">(see section 4.8</span></em>).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="text-autospace:none"><u><span lang="EN-GB">Falls</span></u></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g., elderly or debilitated patients; see section 4.2).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><u><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Sodium</span></u></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Abilify Maintena contains less than 1 mmol of sodium (23 mg) per dose.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.5     Interaction with other medicinal products and other forms of interaction</span></b></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">No interaction studies have been performed with Abilify Maintena. The information below is obtained from studies with oral aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Due to its α1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Potential for other medicinal products to affect aripiprazole</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Quinidine and other strong CYP2D6 inhibitors</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while C<sub>max</sub> was unchanged. The AUC and C<sub>max</sub> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reduction should, therefore, be applied (see section 4.2).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Ketoconazole and other strong CYP3A4 inhibitors</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max</sub> by 63 % and 37 %, respectively. The AUC and C<sub>max</sub> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2). When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Carbamazepine and other CYP3A4 inducers</span></em></p><p class="MsoNormal"><span class="BMSHeading3Char"><span lang="EN-GB" style='font-family:"Times New Roman",serif;font-weight:normal'>Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole</span></span><span class="BMSHeading3Char"><i><span lang="EN-GB" style='font-family:"Times New Roman",serif'> </span></i></span><em><span lang="EN-GB" style="color:black;font-style:normal">to patients with schizophrenia or schizoaffective disorder, the geometric means of C<sub>max</sub> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when oral aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of C<sub>max</sub> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with oral aripiprazole alone. Concomitant administration of Abilify Maintena and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects. The concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided because the blood levels of aripiprazole are decreased and may be below the effective levels.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><i><span lang="EN-GB">Serotonin syndrome</span></i></p><p class="MsoNormal"><span lang="EN-GB">Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.6     Fertility, pregnancy and lactation</span></b></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Pregnancy</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with <em><span style="font-style:normal">aripiprazole</span></em>. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Prescribers need to be aware of the long-acting properties of <em><span style="color:black; font-style:normal">Abilify Maintena</span></em>.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">New-born infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, new-born infants should be monitored carefully (see section 4.8).</span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Breast-feeding</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole is excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from aripiprazole therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Fertility</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p><span lang="EN-GB">Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</span></p><p><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.7     Effects on ability to drive and use machines</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole </span></em><span lang="EN-GB">has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.8     Undesirable effects</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Summary of the safety profile</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The most frequently observed adverse drug reactions (ADRs) reported in ≥ 5 % of patients in two double‑blind, long-term trials of Abilify Maintena were weight increased (9.0 %), akathisia (7.9 %), insomnia (5.8 %), and injection site pain (5.1 %).</span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Tabulated list of adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The incidences of the ADRs associated with aripiprazole therapy are tabulated below. The table is based on adverse reactions reported during clinical trials and/or post-marketing use.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as "not known".</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none" width="614"> <thead> <tr style="height:27.4pt"> <td style="width:78.0pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:27.4pt" valign="top" width="104"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:85.05pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Common</span></b></p> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:141.75pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Uncommon</span></b></p> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:155.9pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Not known</span></b></p> </td> </tr> </thead> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Blood and lymphatic system   disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutropenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thrombocytopenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Neutrophil count decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">White blood cell count decreased</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Leukopenia</span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Immune system disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersensitivity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Allergic reaction (e.g. anaphylactic   reaction, angioedema including swollen tongue, tongue oedema, face oedema,   pruritus, or urticaria)</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Endocrine disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood prolactin decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperprolactinaemia</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Diabetic hyperosmolar coma</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Diabetic ketoacidosis</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Metabolism and nutrition disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Weight increased</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diabetes mellitus</span></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Weight decreased</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperglycaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypercholesterolaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperinsulinaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hyperlipidaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertriglyceridaemia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Appetite disorder</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Anorexia</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Hyponatraemia</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Psychiatric disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Agitation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Anxiety</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restlessness</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Insomnia</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Suicidal ideation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Psychotic disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hallucination</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Delusion</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypersexuality</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Panic reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Depression</span></p> <p class="MsoNormal"><span lang="EN-GB" style="color:black">Affect lability</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Apathy</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysphoria</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sleep disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bruxism</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Libido decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Mood altered</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Completed suicide</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Suicide attempt</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Pathological gambling</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Impulse-control disorders</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Binge eating</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Compulsive shopping</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Poriomania</span></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Nervousness</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Aggression</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Nervous system disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Extrapyramidal disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Akathisia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tremor</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sedation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Somnolence</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dizziness</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Headache</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dystonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tardive dyskinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Parkinsonism</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Movement disorder</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Psychomotor hyperactivity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Restless legs syndrome</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cogwheel rigidity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertonia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradykinesia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Drooling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dysgeusia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Parosmia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Neuroleptic malignant syndrome</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Grand mal convulsion</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Serotonin syndrome</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Speech disorder</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Eye disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Oculogyric crisis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vision blurred</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Eye pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diplopia</span></p> <p class="MsoNormal" style="text-autospace:none"><span style="color:black">Photophobia</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Cardiac disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Ventricular extrasystoles</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Bradycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Tachycardia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Electrocardiogram T wave amplitude decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Electrocardiogram abnormal</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Electrocardiogram T wave inversion</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Sudden unexplained death</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Cardiac arrest</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Torsades de pointes</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Ventricular arrhythmias</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">QT prolongation</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Vascular disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hypertension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Orthostatic hypotension</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood pressure increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Syncope</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Venous thromboembolism (including   pulmonary embolism and deep vein thrombosis)</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Respiratory, thoracic and   mediastinal disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cough</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Hiccups</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Oropharyngeal spasm</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Laryngospasm</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Aspiration pneumonia</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Gastrointestinal disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dry mouth</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gastrooesophageal reflux disease</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Dyspepsia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vomiting</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Diarrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nausea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal pain upper</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Abdominal discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Constipation</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Frequent bowel movement</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Salivary hypersecretion</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Pancreatitis</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Dysphagia</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Hepatobiliary disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Liver function test abnormal Hepatic enzyme increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alanine aminotransferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gamma-glutamyl transferase increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood bilirubin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Aspartate aminotransferase increased</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Hepatic failure</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Jaundice</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Hepatitis</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Alkaline phosphatase increased</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p class="MsoNormal" style="text-autospace:none"><b><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Alopecia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Acne</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Rosacea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Eczema</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Skin induration</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span style="color:black;   font-style:normal">Rash</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span style="color:black;   font-style:normal">Photosensitivity reaction</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span style="color:black;   font-style:normal">Hyperhidrosis</span></em></p> <p class="MsoNormal" style="text-autospace:none">Drug Reaction with   Eosinophilia and Systemic Symptoms (DRESS)</p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Musculoskeletal and connective   tissue disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Musculoskeletal stiffness</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Muscle rigidity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Muscle spasms</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Muscle twitching</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Muscle tightness</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Myalgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pain in extremity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Arthralgia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Back pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Joint range of motion decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nuchal rigidity</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Trismus</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Rhabdomyolysis</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Renal and urinary disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Nephrolithiasis</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosuria</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Urinary retention</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Urinary incontinence</span></em></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Pregnancy, puerperium and perinatal conditions</span></b></em></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Drug withdrawal syndrome neonatal (see   section 4.6)</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Reproductive system and breast   disorders</span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Erectile dysfunction</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Galactorrhoea</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gynaecomastia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Breast tenderness</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Vulvovaginal dryness</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Priapism</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">General disorders and   administration site conditions</span></b></p> <p><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site pain</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site induration Fatigue</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Pyrexia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Asthenia</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Gait disturbance</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Chest discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site reaction</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site erythema</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site swelling</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site discomfort</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Injection site pruritus</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Thirst</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Sluggishness </span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Temperature regulation disorder (e.g.   hypothermia, pyrexia)</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Chest pain</span></em></p> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Peripheral oedema</span></em></p> </td> </tr> <tr> <td style="width:78.0pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="104"> <p><b><span lang="EN-GB" style="color:black">Investigations</span></b></p> <p><b><span lang="EN-GB" style="color:black"> </span></b></p> </td> <td style="width:85.05pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="113"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood creatine phosphokinase increased</span></p> </td> <td style="width:141.75pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="189"> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood glucose decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Glycosylated haemoglobin increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Waist circumference increased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood cholesterol decreased</span></p> <p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Blood triglycerides decreased</span></p> </td> <td style="width:155.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="208"> <p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">Blood glucose fluctuation</span></em></p> </td> </tr> </table><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Description of selected adverse reactions</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Injection site reactions</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">During the double‑blind, controlled phases of the two long-term trials, injection site reactions were observed; those seen were generally mild to moderate in severity, and resolved over time. </span></em><span lang="EN-GB">Injection site pain (incidence 5.1 %), had a median onset on day 2 after the injection and a median duration of 4 days.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB">In an open label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site related reactions were slightly more frequent in the deltoid muscle. The majority were mild and improved on subsequent injections. When compared to studies where Abilify Maintena was injected in the gluteal muscle, repeated occurrence of injection site pain was more frequent in the deltoid muscle.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><i><span lang="EN-GB">Leukopenia</span></i></p><p class="MsoNormal"><span lang="EN-GB">Neutropenia has been reported in the clinical program with <em><span style="color:black;font-style:normal">Abilify Maintena</span></em> and typically started around day 16 after first injection, and lasted a median of 18 days.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Extrapyramidal Symptoms (EPS)</span></em></p><p class="MsoNormal"><span lang="EN-GB">In trials in stable patients with schizophrenia, <em><span style="color:black;font-style:normal">Abilify Maintena</span></em> was associated with a higher frequency of EPS symptoms (18.4 %) than oral aripiprazole treatment (11.7 %). Akathisia was the most frequently observed symptom (8.2 %) and typically started around day 10 after first injection, and lasted a median of 56 days. Subjects with akathisia typically received anti-cholinergic medicines as treatment, primarily benzatropine mesilate and trihexyphenidyl. Less often substances such as propranolol and benzodiazepines (clonazepam and diazepam) were administered to control akathisia. Parkinsonism events followed in frequency of 6.9 % for <em><span style="color:black;font-style:normal">Abilify Maintena</span></em>, 4.15 % for oral aripiprazole 10‑30 mg tablets and 3.0 % for placebo, respectively.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Dystonia</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Weight</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">During the Double-blind, Active-controlled Phase of the 38‑week long-term trial, the incidence of weight gain of </span></em><em><span lang="EN-GB" style="font-family:Symbol;color:black;font-style:normal">³</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> 7 % from baseline to last visit was 9.5 % for Abilify Maintena and 11.7 % for the oral aripiprazole tablets 10‑30 mg. The incidence of weight loss of ≥ 7 % from baseline to last visit was 10.2 % for Abilify Maintena and 4.5 % for oral aripiprazole tablets 10‑30 mg. During the Double-blind, Placebo-controlled Phase of the 52‑week long-term trial, the incidence of weight gain of </span></em><em><span lang="EN-GB" style="font-family:Symbol;color:black;font-style:normal">³</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> 7 % from baseline to last visit was 6.4 % for Abilify Maintena and 5.2 % for placebo. The incidence of weight loss of ≥ 7 % from baseline to last visit was 6.4 % for Abilify Maintena and 6.7 % for placebo. During double‑blind treatment, mean change in body weight from baseline to last visit was ‑0.2 kg for Abilify Maintena and ‑0.4 kg for placebo (p = 0.812).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><i><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Prolactin</span></i></p><p class="BodytextAgency" style="margin-bottom:0in;line-height:normal"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="text-autospace:none"><i><span lang="EN-GB">Pathological gambling and other impulse control disorders</span></i></p><p class="MsoNormal"><span lang="EN-GB">Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see section 4.4).</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Reporting of suspected adverse reactions</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via </span></em><span lang="EN-GB" style="background:silver">the national reporting system listed in </span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><u><span style="background:silver">Appendix V</span></u></a>.</span></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">4.9     Overdose</span></b></em></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">No cases of overdose associated with adverse reactions were reported in clinical studies with <em><span style="color:black;font-style:normal">Abilify Maintena</span></em>. Care must be taken to avoid inadvertent injection of this medicinal product into a blood vessel. Following any confirmed or suspected accidental overdose/inadvertent intravenous administration, close observation of the patient is needed and if any potentially medically serious sign or symptom develops, monitoring, which should include continuous electrocardiographic monitoring, is required. The medical supervision and monitoring should continue until the patient recovers.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">A simulation of dose dumping showed that the predicted median aripiprazole concentration reaches a peak of 4,500 ng/ml or approximately 9 times the upper therapeutic range. In case of dose dumping, aripiprazole concentrations are predicted to descend rapidly to the upper limit of the therapeutic window after approximately 3 days. By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping. <span style="color:black">While overdose is less likely with parenteral than oral medicinal products, reference information for oral aripiprazole overdose is presented below.</span></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Signs and symptoms</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg (41 times highest recommended daily aripiprazole dose) with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore, cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Haemodialysis</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">5.       PHARMACOLOGICAL PROPERTIES</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">5.1     Pharmacodynamic properties</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Pharmacotherapeutic group: Psycholeptics, other antipsychotics, ATC code: N05AX12</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Mechanism of action</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">It has been proposed that aripiprazole’s efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5‑HT<sub>1A</sub> receptors and antagonism at serotonin 5‑HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity. Aripiprazole exhibits high binding affinity </span></em><em><span lang="EN-GB" style="color:black">in vitro</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5‑HT<sub>1A</sub> and 5‑HT<sub>2A</sub> receptors and has moderate affinity for dopamine D<sub>4</sub>, serotonin 5‑HT<sub>2C</sub> and 5‑HT<sub>7</sub>, alpha-1 adrenergic, and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for cholinergic muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole oral doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C‑raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Clinical efficacy and safety</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Maintenance treatment of schizophrenia in adults</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double‑blind, long-term trials.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The pivotal trial was a 38 week, randomised, double‑blind, active‑controlled trial designed to establish the efficacy, safety, and tolerability of this medicinal product administered as monthly injections compared to once daily oral aripiprazole tablets 10‑30 mg as maintenance treatment in adult patients with schizophrenia. This trial consisted of a screening phase and 3 treatment phases: Conversion Phase, Oral Stabilisation Phase, and Double-blind, Active-controlled Phase.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Six-hundred and sixty two patients eligible for the 38‑week Double-blind, Active-controlled Phase were randomly assigned in a 2:2:1 ratio to double‑blind treatment to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation dose of oral aripiprazole 10‑30 mg, or 3) aripiprazole Long-Acting Injectable 50 mg/25 mg. The aripiprazole Long-Acting Injectable 50 mg/25 mg dose was included as a low dose aripiprazole to test assay sensitivity for the non-inferiority design.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The results of analysis of the primary efficacy endpoint, the estimated proportion of patients experiencing impending relapse by end of Week 26 of the Double-blind, Active-controlled Phase, showed that Abilify Maintena 400 mg/300 mg is non-inferior to aripiprazole oral tablets 10‑30 mg.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The estimated relapse rate by end of Week 26 was 7.12 % for Abilify Maintena, and 7.76 % for oral aripiprazole tablets 10‑30 mg, a difference of </span></em><em><span style="color:black;font-style:normal">−</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">0.64 %.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The 95 % CI (</span></em><em><span style="color:black;font-style:normal">−</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">5.26, 3.99) for the difference in the estimated proportion of patients experiencing impending relapse by end of Week 26 excluded the predefined non-inferiority margin, 11.5 %. Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10‑30 mg.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The estimated proportion of patients experiencing impending relapse by end of Week 26 for Abilify Maintena was 7.12 %, which was statistically significantly lower than in aripiprazole Long-Acting Injectable 50 mg/25 mg (21.80 %; p = 0.0006). Thus, superiority of Abilify Maintena over the aripiprazole Long-Acting Injectable 50 mg/25 mg was established and the validity of the trial design was confirmed.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The Kaplan-Meier curves of the time from randomisation to impending relapse during the 38‑week, Double-blind, Active-controlled Phase for Abilify Maintena, oral aripiprazole 10‑30 mg, and aripiprazole Long-Acting Injectable 50 mg/25 mg are shown in Figure 1.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="margin-left:56.7pt;text-indent:-56.7pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Figure 1      Kaplan-Meier Product Limit Plot for Time to Exacerbation of Psychotic Symptoms/Impending Relapse</span></b></em></p><p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB"><img border="0" height="334" id="Grafik 3207" src="#image0" width="535"/></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-size:8.0pt;color:black; font-style:normal">NOTE: ARIP IMD 400/300 mg = Abilify Maintena;ARIP 10‑30 mg = oral aripiprazole; ARIP IMD 50/25 mg = Long-acting Injectable</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Further, the non-inferiority of Abilify Maintena compared to oral aripiprazole 10‑30 mg is supported by the results of the analysis of the Positive and Negative Syndrome Scale score (PANSS).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="margin-left:56.7pt;text-indent:-56.7pt;page-break-after: avoid"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Table 1       PANSS Total Score – Change From Baseline to Week 38-LOCF:<br/> Randomised Efficacy Sample<sup>a, b</sup></span></b></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.2%;margin-left:5.5pt;border-collapse:collapse;border:none" width="99%"> <tr style="height:28.25pt"> <td colspan="4" style="width:100.0%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:28.25pt" valign="top" width="100%"> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal">PANSS Total Score – Change   From Baseline to Week 38-LOCF:</span></b></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><b><span lang="EN-GB" style="color:black;font-style:normal">Randomised Efficacy Sample<sup>a,   b</sup></span></b></em></p> </td> </tr> <tr style="height:38.85pt"> <td style="width:24.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.85pt" valign="top" width="24%"> <p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p> </td> <td style="width:19.48%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:38.85pt" valign="top" width="19%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal"> 400 mg/300 mg</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">(n = 263)</span></em></p> </td> <td style="width:24.82%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:38.85pt" valign="top" width="24%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">Oral aripiprazole</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">10‑30 mg/day</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">(n = 266)</span></em></p> </td> <td style="width:30.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:38.85pt" valign="top" width="30%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole Long-Acting   Injectable</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">50 mg/25 mg</span></em></p> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">(n = 131)</span></em></p> </td> </tr> <tr style="height:16.55pt"> <td style="width:24.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="24%"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Mean baseline (SD)</span></b></em></p> </td> <td style="width:19.48%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="19%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">57.9 (12.94)</span></em></p> </td> <td style="width:24.82%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="24%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">56.6 (12.65)</span></em></p> </td> <td style="width:30.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="30%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">56.1 (12.59)</span></em></p> </td> </tr> <tr style="height:16.55pt"> <td style="width:24.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="24%"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">Mean change (SD)</span></b></em></p> </td> <td style="width:19.48%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="19%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span style="color:black;font-style:normal">−</span></em><em><span lang="EN-GB" style="color:black;font-style:normal">1.8 (10.49)</span></em></p> </td> <td style="width:24.82%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="24%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">0.7 (11.60)</span></em></p> </td> <td style="width:30.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.55pt" valign="top" width="30%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">3.2 (14.45)</span></em></p> </td> </tr> <tr style="height:12.7pt"> <td style="width:24.94%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.7pt" valign="top" width="24%"> <p class="MsoNormal"><em><b><span lang="EN-GB" style="color:black;font-style:   normal">P-value</span></b></em></p> </td> <td style="width:19.48%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.7pt" valign="top" width="19%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">NA</span></em></p> </td> <td style="width:24.82%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.7pt" valign="top" width="24%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">0.0272</span></em></p> </td> <td style="width:30.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:12.7pt" valign="top" width="30%"> <p align="center" class="MsoNormal" style="text-align:center"><em><span lang="EN-GB" style="color:black;font-style:normal">0.0002</span></em></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><em><span lang="EN-GB" style="font-size:8.0pt;color:black;font-style:normal">a:    Negative change in score indicates improvement.</span></em></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><em><span lang="EN-GB" style="font-size:8.0pt;color:black;font-style:normal">b:   Only patients having both baseline and at least one post baseline were included. P-values were derived from comparison for change from baseline within analysis of covariance model with treatment as term and baseline as covariate.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The second trial was a 52‑week, randomised, withdrawal, double‑blind, trial conducted in US adult patients with a current diagnosis of schizophrenia. This trial consisted of a screening phase and 4 treatment phases: Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and Double-blind Placebo-controlled. Patients fulfilling the oral stabilisation requirement in the Oral Stabilisation Phase were assigned to receive, in a single-blind fashion, Abilify Maintena and began an Abilify Maintena Stabilisation Phase for a minimum of 12 weeks and a maximum of 36 weeks. Patients eligible for the Double-blind, Placebo-controlled Phase were randomly assigned in a 2:1 ratio to double‑blind treatment with Abilify Maintena or placebo, respectively.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The final efficacy analysis included 403 randomised patients and 80 exacerbations of psychotic symptoms/impending relapse events. In the placebo group 39.6 % of the patients had progressed to impending relapse, whilst in the Abilify Maintena group impending relapse occurred in 10 % of the patients; thus patients in the placebo group had a 5.03‑fold greater risk of experiencing impending relapse.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Prolactin</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In the Double-blind, Active-controlled Phase of the 38‑week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.33 ng/ml) compared with a mean increase in oral aripiprazole tablets 10‑30 mg (0.79 ng/ml; p &lt; 0.01). The incidence of Abilify Maintena patients with prolactin levels &gt; 1 time the upper limit of normal range (ULN) at any assessment was 5.4 % compared with 3.5 % of the patients on oral aripiprazole tablets 10‑30 mg.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Male patients generally had a higher incidence than female patients in each treatment group.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In the Double-blind Placebo-controlled Phase of the 52‑week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.38 ng/ml) compared with a mean increase in placebo (1.67 ng/ml). The incidences of Abilify Maintena patients with prolactin levels &gt; 1 time the upper limit of normal range (ULN) was 1.9 % compared to 7.1 % for placebo patients.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><i><span lang="EN-GB">Acute treatment of schizophrenia in adults</span></i></p><p class="MsoNormal"><span lang="EN-GB">The efficacy of Abilify Maintena in acutely relapsed adult patients with schizophrenia was established in a short-term (12-week), randomised, double‑blind, placebo-controlled trial (n = 339).</span></p><p class="MsoNormal"><span lang="EN-GB">The primary endpoint (change in PANSS total score from baseline to week 10) showed superiority of Abilify Maintena (n = 167) over placebo (n = 172).</span></p><p class="MsoNormal"><span lang="EN-GB">Similar to the PANSS Total Score, both the PANSS positive and negative subscale scores also showed an improvement (decrease) from baseline over time.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:56.7pt;text-indent:-56.7pt;page-break-after: avoid"><b><span lang="EN-GB" style="color:black">Table 2       PANSS Total Score – Change From Baseline to week 10: Randomised Efficacy Sample</span></b></p><p class="MsoNormal" style="margin-left:56.7pt;text-indent:-56.7pt;page-break-after: avoid"><b><span lang="EN-GB" style="color:black"> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="margin-left:5.4pt;border-collapse:collapse;border:none"> <tr> <td colspan="3" style="width:458.95pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="612"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB" style="color:black">PANSS Total Score – Change   From Baseline to Week 10:</span></b></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><b><span lang="EN-GB" style="color:black">Randomised Efficacy Sample <sup>a</sup></span></b></p> </td> </tr> <tr> <td style="width:191.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><b><sup><span lang="EN-GB"> </span></sup></b></p> </td> <td style="width:134.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB" style="color:black">Abilify Maintena</span></b></p> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB" style="color:black">400 mg/300 mg</span></b></p> </td> <td style="width:132.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="177"> <p align="center" class="MsoNormal" style="text-align:center"><b><span lang="EN-GB" style="color:black">Placebo</span></b></p> <p class="MsoNormal"><b><sup><span lang="EN-GB"> </span></sup></b></p> </td> </tr> <tr> <td style="width:191.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">Mean baseline (SD)</span></b></p> </td> <td style="width:134.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><span lang="EN-GB">102.4 (11.4)</span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">n = 162</span></p> </td> <td style="width:132.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="177"> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><span lang="EN-GB">103.4 (11.1)</span></p> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><span lang="EN-GB">n = 167</span></p> </td> </tr> <tr> <td style="width:191.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">LS Mean change   (SE)</span></b></p> </td> <td style="width:134.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><em><span style="color:black;font-style:normal">−</span></em><span lang="EN-GB">26.8   (1.6)</span></p> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">n = 99</span></p> </td> <td style="width:132.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="177"> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><em><span style="color:black;font-style:normal">−</span></em><span lang="EN-GB">11.7   (1.6)</span></p> <p align="center" class="MsoNormal" style="margin-right:5.65pt;text-align:center"><span lang="EN-GB">n = 81</span></p> </td> </tr> <tr> <td style="width:191.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="255"> <p class="MsoNormal"><b><span lang="EN-GB" style="color:black">P-value</span></b></p> </td> <td style="width:134.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center"><span lang="EN-GB">&lt; 0.0001</span></p> </td> <td style="width:132.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="177"> <p class="MsoNormal"><b><sup><span lang="EN-GB"> </span></sup></b></p> </td> </tr> <tr style="height:3.2pt"> <td style="width:191.4pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt" valign="top" width="255"> <p class="MsoNormal"><b><span lang="EN-GB">Treatment difference<sup>b</sup>   (95 % CI)</span></b></p> </td> <td style="width:134.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:3.2pt" valign="top" width="180"> <p align="center" class="MsoNormal" style="text-align:center"><em><span style="color:black;font-style:normal">−</span></em><span lang="EN-GB">15.1   (</span><em><span style="color:black;font-style:normal">−</span></em><span lang="EN-GB">19.4, </span><em><span style="color:black;font-style:normal">−</span></em><span lang="EN-GB">10.8)</span></p> </td> <td style="width:132.9pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:3.2pt" valign="top" width="177"> <p class="MsoNormal"><b><sup><span lang="EN-GB"> </span></sup></b></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><sup><span lang="EN-GB" style="font-size:8.0pt">a        </span></sup><span lang="EN-GB" style="font-size:8.0pt">Data were analysed using a mixed model repeated measures (MMRM) approach. The analysis included only subjects who were randomly assigned to treatment, given at least one injection, had baseline and at least one post-baseline efficacy assessment.</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><sup><span lang="EN-GB" style="font-size:8.0pt">b        </span></sup><span lang="EN-GB" style="font-size:8.0pt">Difference (Abilify Maintena minus placebo) in least squares mean change from baseline.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Abilify Maintena also showed statistically significant improvement in symptoms represented by CGIS score change from baseline to week 10.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Personal and social functioning were evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. There was a statistically significant treatment difference in favour of Abilify Maintena 400 mg/300 mg compared to placebo at week 10 (+7.1, p &lt; 0.0001, 95 % CI: 4.1, 10.1 using an ANCOVA model (LOCF)).</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The safety profile was consistent with that known to Abilify Maintena. Nevertheless, there were differences from what has been observed with maintenance use in the treatment of schizophrenia. In </span><span lang="EN-GB">a short-term (12-week), randomised, double‑blind, placebo-controlled trial with <span style="color:black">Abilify Maintena 400</span> <span style="color:black">mg/300</span> <span style="color:black">mg treated subjects the symptoms which had at least twice the incidence of placebo were increased weight and akathisia. The incidence of weight gain of ≥ 7 % from baseline to last visit (week</span> <span style="color:black">12) was 21.5 % for Abilify Maintena compared with the placebo group 8.5 %. Akathisia was the most frequently observed EPS symptom (Abilify Maintena 11.4</span> <span style="color:black">% and placebo group 3.5 %).</span></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Paediatric population</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The European Medicines Agency has waived the obligation to submit the results of studies with Abilify Maintena in all subsets of the paediatric population in schizophrenia (see section 4.2).</span></em></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">5.2     Pharmacokinetic properties</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Absorption</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole absorption into the systemic circulation is slow and prolonged following Abilify Maintena administration due to low solubility of aripiprazole particles.</span></em><span lang="EN-GB">The <span style="color:black">average absorption half-life of <em><span style="font-style:normal">Abilify Maintena</span></em> is 28 days.<em><span style="font-style:normal"> </span></em></span>Absorption of aripiprazole from the IM depot formulation was complete relative to the IM standard (immediate-release) formulation<span style="color:black">. The dose adjusted C<sub>max</sub> values for the depot formulation were approximately 5<em><span style="font-style:normal"> </span></em>% of C<sub>max</sub> from IM standard formulation.</span>Following a single dose administration of Abilify Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was similar for both injection sites, but the rate of absorption (C<sub>max</sub>) was higher following administration to the deltoid muscle. Following multiple intramuscular doses, the plasma concentrations of aripiprazole gradually rise to a maximum plasma concentration at a median t<sub>max </sub>of 7 days for the gluteal muscle and 4 days for the deltoid muscle. Steady state concentrations for the typical subject were attained by the fourth dose for both sites of administration. <em><span style="color:black;font-style:normal">Less than dose-proportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters are observed after monthly Abilify Maintena injections of 300 mg to 400 mg.</span></em></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Distribution</span></u></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Biotransformation</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on </span></em><em><span lang="EN-GB" style="color:black">in vitro</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. After multiple dose administration of Abilify Maintena, dehydro-aripiprazole, the active metabolite, represents about 29.1‑32.5 % of aripiprazole AUC in plasma.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Elimination</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days </span></em><span lang="EN-GB" style="color:black">presumably due to absorption rate-limited kinetics.<em><span style="font-style:normal"> Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</span></em></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Pharmacokinetics in special patient groups</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">CYP2D6 poor metabolisers</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Based on population pharmacokinetic evaluation of Abilify Maintena, the total body clearance of aripiprazole was 3.71 L/h in extensive metabolisers of CYP2D6 and approximately 1.88 L/h (approximately 50 % lower) in poor metabolisers of CYP2D6 (for dose recommendation, see section 4.2).</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Elderly</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects. Similarly, there was no detectable effect of age in a population pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.</span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Gender</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects. Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Smoking</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Population pharmacokinetic evaluation of oral aripiprazole has revealed no evidence of clinically relevant effects from smoking on the pharmacokinetics of aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Race</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Renal impairment</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In a single-dose study with oral administration of aripiprazole, the pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to that in young healthy subjects.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Hepatic impairment</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">A single-dose study with oral administration of aripiprazole to subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">5.3     Preclinical safety data</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is generally similar to that seen following oral administration at comparable plasma levels. With intramuscular injection, however </span></em><span lang="EN-GB" style="color:black">an inflammatory response was seen at the injection site, and consisted of granulomatous inflammation, foci (deposited drug), cellular infiltrates, oedema (swelling) and, in monkeys, fibrosis. <em><span style="font-style:normal">These effects gradually resolved with discontinuation of dosing.</span></em></span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Non-clinical safety data for orally administered aripiprazole reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Oral aripiprazole</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">For oral aripiprazole, toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity in rats after 104 weeks of oral administration at approximately 3 to 10 times the mean steady-state AUC at the maximum recommended human dose and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at approximately 10 times the mean steady-state AUC at the maximum recommended human dose. The highest non-tumorigenic exposure in female rats was approximately 7 times the human exposure at the recommended dose.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy-metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day or approximately16 to 81 times the maximum recommended human dose based on mg/m<sup>2</sup>.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">However, the concentrations of the sulphate conjugates of hydroxy-aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39‑week study and are well below (6 %) their limits of </span></em><em><span lang="EN-GB" style="color:black">in vitro</span></em><em><span lang="EN-GB" style="color:black;font-style:normal"> solubility.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">In repeated dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse events on development.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in sub-therapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures approximately 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.       PHARMACEUTICAL PARTICULARS</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.1     List of excipients</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Powder</span></u></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal"><span style="text-decoration:none"> </span></span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Carmellose sodium</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Mannitol</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Sodium dihydrogen phosphate monohydrate</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Sodium hydroxide</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Solvent</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Water for injections</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.2     Incompatibilities</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Not applicable</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.3     Shelf life</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">3 years</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Abilify Maintena powder and solvent for prolonged-release suspension for injection</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The suspension should be injected immediately after reconstitution but can be stored below 25 °C for up to 4 hours in the vial.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Abilify Maintena powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The suspension should be injected immediately after reconstitution but can be stored below 25 °C for up to 2 hours in the syringe.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">After reconstitution</span></i></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black"> </span></i></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Chemical and physical in-use stability has been demonstrated for 4 hours at 25 °C. From a microbiological point of view, unless the method of opening/ reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of user. Do not store the reconstituted suspension in the syringe.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">If the injection is not performed immediately after reconstitution, the syringe can be kept below 25 °C for up to 2 hours.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.4     Special precautions for storage</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Do not freeze.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Keep the syringe in the outer carton in order to protect from light.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB">For storage conditions after reconstitution of the medicinal product, see section 6.3.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.5     Nature and contents of container</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Vial</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Type‑I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Solvent</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">2 ml Type‑1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Single pack</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each single pack containing one vial of powder, 2 ml vial of solvent, one 3 ml luer lock syringe with pre-attached 38 mm (1.5 inch) 21 gauge, hypodermic safety needle with needle protection device, one 3 ml disposable syringe with luer lock tip, one vial adapter and three hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Multipack</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Bundle pack of 3 single packs.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Clear glass pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-, middle- and end stopper), polypropylene front assembly, polypropylene finger grip, plunger rod, and silicone over-cap. The front chamber between front stopper and middle stopper contains the powder and the rear chamber between middle stopper and end stopper the solvent.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Single pack</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Each single pack containing one pre‑filled syringe, and three hypodermic safety needles: one 25 mm (1 inch) 23 gauge, one 38 mm (1.5 inch) 22 gauge and one 51 mm (2 inch) 21 gauge.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Multipack</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Bundle pack of 3 single packs.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Not all pack sizes may be marketed.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">6.6     Special precautions for disposal and other handling</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Shake the vial vigorously for at least 30 seconds until the suspension appears uniform.</span></p><p class="MsoNormal"><span lang="EN-GB">If the injection is not performed immediately after reconstitution shake it vigorously for at least 60 seconds to re‑suspend prior to injection.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal" style="page-break-after:avoid"><em><span lang="EN-GB" style="color:black"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Vertically shake the syringe vigorously for 20 seconds until medicine is uniformly milky-white and use immediately. If the injection is not performed immediately after reconstitution, the syringe can be kept below 25 °C for up to 2 hours. Shake the syringe vigorously for at least 20 seconds to re‑suspend prior to injection if the syringe has been left for more than 15 minutes.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Gluteal muscle administration</span></em></p><p class="MsoNormal" style="text-autospace:none"><em><span lang="EN-GB" style="color:black;font-style:normal">The recommended needle for gluteal administration is a 38 mm (1.5 inch), 22 gauge hypodermic safety needle; for obese patients (Body mass index &gt; 28 kg/m<sup>2</sup>), a 51 mm (2 inch), 21 gauge hypodermic safety needle should be used. </span></em><span lang="EN-GB">Gluteal injections should be alternated between the two gluteal muscles.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black">Deltoid muscle administration</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal">The recommended needle for deltoid administration is a 25 mm (1 inch), 23 gauge hypodermic safety needle; for obese patients, a 38 mm (1.5 inch), 22 gauge hypodermic safety needle should be used.</span></em></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB">Deltoid injections should be alternated between the two deltoid muscles.</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">The powder and solvent vials and the pre‑filled syringe are for single-use only.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Discard vial, adapter, syringe, needles, unused suspension and water for injections appropriately.</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Full instructions for use and handling of Abilify Maintena are provided in the package leaflet (information intended for healthcare professionals).</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">7.       MARKETING AUTHORISATION HOLDER</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB">Otsuka Pharmaceutical Netherlands B.V.</span></p><p class="MsoNormal"><span lang="EN-GB">Herikerbergweg 292</span></p><p class="MsoNormal"><span lang="EN-GB">1101 CT, Amsterdam</span></p><p class="MsoNormal"><span lang="EN-GB">Netherlands</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S)"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">8.       MARKETING AUTHORISATION NUMBER(S)</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/001</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/003</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection</span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/002</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/004</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/005</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/007</span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><u><span lang="EN-GB" style="color:black;font-style:normal">Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre‑filled syringe</span></u></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/006</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">EU/1/13/882/008</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Date of first authorisation: 15 November 2013</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal">Date of latest renewal: 27 August 2018</span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><em><b><span lang="EN-GB" style="color:black;font-style:normal">10.     DATE OF REVISION OF THE TEXT</span></b></em></p><p class="MsoNormal"><em><span lang="EN-GB" style="color:black;font-style:normal"> </span></em></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">MM/YYYY</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a href="http://www.ema.europa.eu/"><u>http://www.ema.europa.eu</u></a>.</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>